San Diego, California; London, UK and Bergisch Gladbach, Germany, December 18, 2023 – Replay, a genome writing company reprogramming biology by writing, designing and delivering big DNA, and Miltenyi ...
NEW YORK, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Cell BioEngines, Inc., a clinical-stage biotechnology company focused on delivering novel, innovative stem cell and immune cell therapies to address blood ...
Miltenyi Biotec opens first office and Technology Center in Hyderabad, India, focusing on Cell and Gene Therapy (CGT). The Center offers training, research, and manufacturing solutions for CGT, using ...
This seminar will give attendees a full overview of two new Miltenyi cell sorting platforms, the MultiMACS X and the CliniMACS Prodigy and how these instruments can be used in various primary cell ...
Through Syena, its oncology-focused product company, Replay will develop and manufacture T-cell receptor and natural killer cell therapies with the NIH and Miltenyi Biotec. On Dec. 18, 2023, Replay, a ...
IsoPlexis, which recently received an NCI grant, reports that it has published a technology note with Miltenyi Biotec in a co-marketing agreement. The tech note (“Getting the most out of your CAR-T ...
Hyderabad: Miltenyi Biotec, a global leader in cell and gene therapy (CGT) solutions, has launched India's first dedicated Cell & Gene Therapy Center of Excellence (CoE) in Hyderabad. Located in ...
Syena secures exclusive license to Miltenyi Biotec’s PRAME TCR Syena, co-founded by Replay and MD Anderson in 2023, will develop an off-the-shelf PRAME TCR-NK cell therapy, with IND anticipated Q1 ...
Cell BioEngines to Leverage Miltenyi’s Expertise and Proven Platforms to Develop and Manufacture Hematopoietic Stem Cell Transplantation (HSCT) Product NEW YORK, Dec. 29, 2023 (GLOBE NEWSWIRE) — Cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback